First human test of new eczema pill shows promise
NCT ID NCT06945458
Summary
This early-stage study tested a new oral medication called KT-621 for adults with moderate to severe eczema. The main goals were to check if the pill was safe and how the body processed it. Researchers enrolled 22 participants to take the drug and monitored them closely for side effects and any changes in their eczema symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kymera Investigative Site
Birmingham, Alabama, 35244, United States
-
Kymera Investigative Site
Fountain Valley, California, 92708, United States
-
Kymera Investigative Site
Santa Monica, California, 90404, United States
-
Kymera Investigative Site
Boynton Beach, Florida, 33436, United States
-
Kymera Investigative Site
Hollywood, Florida, 33024, United States
-
Kymera Investigative Site
Tampa, Florida, 33613, United States
-
Kymera Investigative Site
Fargo, North Dakota, 58078, United States
-
Kymera Investigative Site
Dublin, Ohio, 43016, United States
-
Kymera Investigative Site
Springfield, Ohio, 45505, United States
-
Kymera Investigative Site
Tulsa, Oklahoma, 74136, United States
-
Kymera Investigative Site
Charleston, South Carolina, 29420, United States
-
Kymera Investigative Site
San Antonio, Texas, 78213, United States
Conditions
Explore the condition pages connected to this study.